Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro

Stem Cell Research

Volumn 14, Issue 2, 2015, Pages 198-210

  Calkoen, F G J ^a   Vervat, C ^a   van Pel, M ^a   de Haas, V ^b   Vijfhuizen, L ^a   Eising, E ^a   Kroes, W G M ^a   't Hoen, P A C ^a   van den Heuvel Eibrink, M M ^b,c   Egeler, R M ^a,d   van Tol, M J D ^a   Ball, L M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Childhood Oncology Group DCOG   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE RECEPTOR LIKE FACTOR 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PROTEIN; PROTEIN DAPK1; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ADOLESCENT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MALE; MALIGNANT TRANSFORMATION; MESENCHYMAL STROMA CELL; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; OSTEOBLAST; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TRISOMY 8; TUMOR MICROENVIRONMENT; CELL CULTURE; CELL PROLIFERATION; CYTOGENETICS; GENETICS; INFANT; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ADOLESCENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOGENETICS; FEMALE; HUMANS; IN VITRO TECHNIQUES; INFANT; MALE; MESENCHYMAL STROMAL CELLS; MYELODYSPLASTIC SYNDROMES; TRANSCRIPTOME;

EID: 84922455690     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2015.01.006     Document Type: Article

References (62)

1. Hasle H., Baumann I., Bergstrasser E., et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004, 18(12):2008-2014.
2. Hasle H., Niemeyer C.M., Chessells J.M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17(2):277-282.
3. Strahm B., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011, 25(3):455-462.
4. Sasaki H., Manabe A., Kojima S., et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001, 15(11):1713-1720.
5. Woods W.G., Barnard D.R., Alonzo T.A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J. Clin. Oncol. 2002, 20(2):434-440.
6. Hasle H., Niemeyer C.M. Advances in the prognostication and management of advanced MDS in children. Br. J. Haematol. 2011, 154(2):185-195.
7. Zhang B., Ho Y.W., Huang Q., et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012, 21(4):577-592.
8. Morikawa S., Mabuchi Y., Kubota Y., et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 2009, 206(11):2483-2496.
9. Mendez-Ferrer S., Michurina T.V., Ferraro F., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466(7308):829-834.
10. Sugiyama T., Kohara H., Noda M., et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25(6):977-988.
11. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464(7290):852-857.
12. Schepers K., Pietras E.M., Reynaud D., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13(3):285-299.
13. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118(20):5583-5592.
14. Lopez-Villar O., Garcia J.L., Sanchez-Guijo F.M., et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 2009, 23(4):664-672.
15. Flores-Figueroa E., Montesinos J.J., Flores-Guzman P., et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk. Res. 2008, 32(9):1407-1416.
16. Marcondes A.M., Mhyre A.J., Stirewalt D.L., et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(8):2865-2870.
17. Santamaria C., Muntion S., Roson B., et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012, 97(8):1218-1224.
18. Wang Z., Tang X., Xu W., et al. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 2013, 8(3):e57470.
19. Zhao Z.G., Xu W., Yu H.P., et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett. 2012, 317(2):136-143.
20. Ferrer R.A., Wobus M., List C., et al. Mesenchymal stromal cells from patients with myelodyplastic syndromedisplay distinct functional alterations that are modulated by lenalidomide. Haematologica 2013, 98(11):1677-1685.
21. Klaus M., Stavroulaki E., Kastrinaki M.C., et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010, 19(7):1043-1054.
22. Alvi S., Shaher A., Shetty V., et al. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leuk. Res. 2001, 25(11):941-954.
23. Aizawa S., Nakano M., Iwase O., et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk. Res. 1999, 23(3):239-246.
24. Narendran A., Hawkins L.M., Ganjavi H., et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr. Hematol. Oncol. 2004, 21(3):209-221.
25. Borojevic R., Roela R.A., Rodarte R.S., et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk. Res. 2004, 28(8):831-844.
26. Roela R.A., Carraro D.M., Brentani H.P., et al. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. Leuk. Res. 2007, 31(5):579-589.
27. Calkoen F.G., Brinkman D.M., Vervat C., et al. Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses. Cytotherapy 2013, 15(3):280-291.
28. Bronkhorst I.H., Maat W., Jordanova E.S., et al. Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch. Pathol. Lab. Med. 2011, 135(8):1042-1047.
29. Lankester A.C., Bierings M.B., van Wering E.R., et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010, 24(8):1462-1469.
30. Mastrokolias A., den Dunnen J.T., van Ommen G.B., et al. Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. BMC Genomics 2012, 13:28.
31. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26(1):139-140.
32. R: A Language and Environment for Statistical Computing 2012, (Vienna, Austria).
33. Smyth G., Gentleman R., VCSDRIWH Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. Springer, New York, NY, USA.
34. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat. Med. 1990, 9(7):811-818.
35. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 2012, 12(5):383-396.
36. Calloni R., Cordero E.A., Henriques J.A., et al. Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev. 2013, 22(9):1455-1476.
37. Chillemi A., Zaccarello G., Quarona V., et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol. Med. 2013, 19:99-108.
38. Zhao Z., Wang Z., Li Q., et al. The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 2012, 7(9):e45675.
39. Oliveira F.M., Lucena-Araujo A.R., Favarin M.C., et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Exp. Hematol. 2013, 41(2):198-208.
40. Gohring G., Michalova K., Beverloo H.B., et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 2010, 116(19):3766-3769.
41. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk. Res. 2002, 26(7):677-686.
42. Minami M., Inoue M., Wei S., et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(9):3963-3966.
43. Zhang H., Nguyen-Jackson H., Panopoulos A.D., et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 2010, 116(14):2462-2471.
44. Csaszar E., Wang W., Usenko T. Blood stem cell fate regulation by delta-1 mediated rewiring of IL-6 paracrine signaling. Blood 2014, 123(5):650-658.
45. Gunn W.G., Conley A., Deininger L., et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006, 24(4):986-991.
46. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer 2010, 46(7):1223-1231.
47. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010, 49(1):15-24.
48. Melief S.M., Geutskens S.B., Fibbe W.E., et al. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013, 98(6):888-895.
49. Song L., Webb N.E., Song Y., et al. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 2006, 24(7):1707-1718.
50. Looyenga B.D., Resau J., MacKeigan J.P. Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. PLoS One 2013, 8(6):e66548.
51. Kass D.J., Yu G., Loh K.S., et al. Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury. Am. J. Pathol. 2012, 180(5):1963-1978.
52. Raval A., Tanner S.M., Byrd J.C., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129(5):879-890.
53. Qian J., Yao D.M., Lin J., et al. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Int. J. Lab. Hematol. 2010, 32(1 Pt 2):74-81.
54. Wu X., Liu W., Tian Y., et al. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes. Acta Haematol. 2011, 125(4):179-185.
55. Claus R., Hackanson B., Poetsch A.R., et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int. J. Cancer 2012, 131(2):E138-E142.
56. Karlic H., Herrmann H., Varga F., et al. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 2014, 90(1):1-16.
57. Glaubach T., Robinson L.J., Corey S.J. Pediatric myelodysplastic syndromes: they do exist!. J. Pediatr. Hematol. Oncol. 2014, 36(1):1-7.
58. Hirabayashi S., Flotho C., Moetter J., et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood 2012, 119(11):e96-e99.
59. Thanopoulou E., Cashman J., Kakagianne T., et al. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004, 103(11):4285-4293.
60. Kerbauy D.M., Lesnikov V., Torok-Storb B., et al. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood 2004, 104(7):2202-2203.
61. Groen R.W., Noort W.A., Raymakers R.A., et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012, 120(3):e9-e16.
62. Walkley C.R., Olsen G.H., Dworkin S., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007, 129(6):1097-1110.